Source: International Congress 2014 – Asthma and COPD management
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Price, M. Thomas, R. Lamarca, E. Garcia Gil (Aberdeen, Southampton, United Kingdom; Barcelona, Spain). Analysis of comorbidities and treatment patterns by GOLD 2013 criteria: Pooled data from Phase III aclidinium bromide studies. Eur Respir J 2014; 44: Suppl. 58, 892

Member's Comments

No comment yet.

Related content which might interest you: Efficacy of aclidinium bromide in patients with stable COPD: Pooled analysis of phase III data by GOLD 2013 criteria Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Effect of aclidinium bromide on dyspnoea and health status in patients with stable COPD: Phase III data by GOLD 2013 classification Source: International Congress 2014 – Asthma and COPD management Year: 2014 Safety of aclidinium bromide/formoterol fumarate fixed dose combination (FDC) in COPD: Pooled analyses of three phase III studies Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Lung function with aclidinium/formoterol fixed-dose combination: Pooled analysis of two phase III studies in COPD Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Effect of aclidinium bromide on exacerbations in patients with moderate-to-severe COPD: Pooled analysis of phase III studies Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Evaluating cardiac safety of tiotropium in patients with COPD: Combined analysis of Holter-ECG data from four trials Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Overall and cardiovascular safety of aclidinium bromide in patients with COPD: Results of a pooled analysis Source: International Congress 2014 – Asthma and COPD management Year: 2014 The effect of twice-daily aclidinium bromide on cough and sputum in patients with COPD: Results from phase III studies Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Cardiovascular (CV) safety of aclidinium bromide/formoterol fumarate fixed dose combination (FDC) in COPD: Pooled analyses of three Phase III studies Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Effect of tiotropium bromide on collagen-IV level: Results from 180-days study in subjects with moderate COPD Source: International Congress 2014 – Markers Year: 2014 Real life distribution of the COPD patients in GOLD groups A to D in German population: DACCORD registry Source: International Congress 2014 – Rationale behind respiratory drug development Year: 2014 Safety profile of glycopyrronium in patients with COPD: An innovative approach to analyse data from post-marketing surveillance (PMS) Source: International Congress 2014 – Asthma and COPD management Year: 2014 Dissociation between clinical trial inclusion and exclusion criteria for trials in severe asthma and the reality of the patient population Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 LATE-BREAKING ABSTRACT: LAVOLTA I and II: Results of 2 phase III studies to assess the efficacy and safety of lebrikizumab in patients with uncontrolled asthma Source: International Congress 2016 – Late-breaking topics in airways disease Year: 2016 Pneumonia risk with budesonide-containing therapies in COPD: pooled analysis of three Phase III studies Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more Year: 2019 Tiotropium vs salmeterol in GOLD II and maintenance-naïve COPD patients: Subgroup analyses of POET-COPDÔ trial Source: Annual Congress 2011 - COPD management Year: 2011 Roflumilast for stable COPD: Meta-analysis of randomized controlled trials Source: International Congress 2014 – Clinical presentations Year: 2014 Analyzing the pathway to triple therapy in COPD patients: A retrospective database analysis Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Real-world prescribing patterns among newly diagnosed COPD patients receiving ICS: An analysis of UK patient dataset Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 As-needed formoterol (F) in asthma: An analysis of the East-Asian subgroup of the RELIEF study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014